Avidity Biosciences Announces Managed Access Program for Duchenne Muscular Dystrophy Therapy

Avidity Biosciences has launched a Managed Access Program (MAP) for investigational therapy delpacibart zotadirsen (del-zota) for people with Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the US. The program aims to provide del-zota to eligible patients as quickly as possible, following an FDA-authorized treatment protocol. Avidity recognizes the need for approved exon skipping therapies for this disease and is optimistic about del-zota's potential based on clinical study data.